The 66th American Society of Hematology Annual Meeting (ASH)

The 66th American Society of Hematology Annual Meeting (ASH)

2024.12.10
The 66th American Society of Hematology Annual Meeting (ASH) was grandly held in San Diego, USA, from December 7th to 10th, 2024. This annual event is one of the most influential scientific communication platforms in the field of hematology worldwide. This edition of the ASH Annual Meeting attracted over 25,000 professionals, including clinicians, scientists, researchers, and healthcare decision-makers from more than 100 countries around the globe. The conference covered all aspects of malignant and non-malignant hematology, from basic scientific research to clinical practice, from drug development to therapeutic innovation, reflecting the latest advancements and future trends in the field of hematology.
The 8th West China Uro-Oncology Tianfu Academic Conference丨Dr. Yige Bao: Perioperative Personalized Treatment of UTUC Based on ADC Drugs and the West

The 8th West China Uro-Oncology Tianfu Academic Conference丨Dr. Yige Bao: Perioperative Personalized Treatment of UTUC Based on ADC Drugs and the West

2024.12.10
Upper tract urothelial carcinoma (UTUC), encompassing renal pelvic and ureteral cancers, is relatively rare, with unique characteristics in the Chinese population, such as distinct disease features and molecular biology profiles. The 8th West China Uro-Oncology Tianfu Academic Conference, recently held in Chengdu, provided a platform to discuss how to better address the challenges in UTUC treatment and improve patient outcomes. In this event, Oncology Frontier interviewed Dr. Yige Bao from West China Hospital of Sichuan University, who shared insights into personalized perioperative treatment of UTUC with ADC drugs and the hospital's clinical experiences.
CCHIO 2024丨Dr. Gang Zhu: Enhancing Patient Rehabilitation Concepts and Individualized Treatment for Multistage Benefits in Prostate Cancer Patients

CCHIO 2024丨Dr. Gang Zhu: Enhancing Patient Rehabilitation Concepts and Individualized Treatment for Multistage Benefits in Prostate Cancer Patients

2024.12.10
With economic development, lifestyle changes, and environmental factors, prostate cancer incidence in China has significantly increased. Screening high-risk populations and providing precision treatment and rehabilitation support based on patient characteristics are crucial for improving cure rates and quality of life. At the 2024 Chinese Congress of Holistic Integrative Oncology (CCHIO), Dr. Gang Zhu, Chair of the Urological Oncology Rehabilitation Committee of the Chinese Anti-Cancer Association and Director of General Surgery and Urology at United Family Healthcare, presented insights on individualized treatment for prostate cancer. Urology Frontier had the opportunity to delve deeper into this topic with Professor Zhu.
An Exploratory Analysis of the PRESERVE 1Trial: Assessing Trilaciclib’s Role in Reducing Chemotherapy-Related Toxicity in Metastatic Colorectal Cancer

An Exploratory Analysis of the PRESERVE 1Trial: Assessing Trilaciclib’s Role in Reducing Chemotherapy-Related Toxicity in Metastatic Colorectal Cancer

2024.12.10
On November 23rd, Dr. Tianshu Liu's team from Zhongshan Hospital published a study titled "Trilaciclib prior to FOLFOXIRI/bevacizumab for patients with untreated metastatic colorectal cancer: phase 3 PRESERVE 1 trial" in JNCI Cancer Spectrum(IF=3.4). The PRESERVE 1 trial sheds light on trilaciclib's potential to reduce chemotherapy-related toxicity in mCRC. While its efficacy in mitigating myelosuppression is evident, the antitumor results are concerning. Further studies are needed to explore the balance between toxicity reduction and efficacy, and to determine trilaciclib's optimal use in cancer treatment.

AASLD 2024丨Dr. Jinlin Hou’s Team: Cost-Effectiveness of aMAP Score-Guided Individualized HCC Screening in HBsAg-Positive Populations

2024.12.10
Hepatocellular carcinoma (HCC) imposes a significant health and economic burden on patients. Screening, recognized as an effective strategy to improve early diagnosis rates in high-risk populations, has garnered broad acknowledgment in the field. Current HCC screening techniques primarily rely on abdominal ultrasound (US) and alpha-fetoprotein (AFP) testing. However, these methods have limitations: the accuracy of ultrasound can be affected by subcutaneous fat thickness, and AFP has a relatively low detection rate for early-stage HCC.
CCHIO 2024 | Dr. Bicheng Zhang: Post-Resistance Strategies for Third-Generation EGFR-TKIs in NSCLC

CCHIO 2024 | Dr. Bicheng Zhang: Post-Resistance Strategies for Third-Generation EGFR-TKIs in NSCLC

2024.12.09
EGFR mutations are among the most common genetic abnormalities in non-squamous non-small cell lung cancer (NSCLC), and EGFR-TKIs have become the standard first-line treatment for advanced EGFR-mutant NSCLC. Despite significant advancements across three generations of EGFR-TKIs, resistance remains unavoidable. Post-resistance treatment options for EGFR-TKI patients, particularly those facing complex third-generation resistance mechanisms, are limited.
CCHIO 2024 | Dr. Huaqing Wang: Exploring Bispecific Antibodies in Lung Cancer

CCHIO 2024 | Dr. Huaqing Wang: Exploring Bispecific Antibodies in Lung Cancer

2024.12.09
Immunotherapy, represented by immune checkpoint inhibitors (ICIs), has rapidly advanced in the treatment of lung cancer in recent years. However, challenges remain, such as limited efficacy with monotherapy and increased side effects with combination therapies. Multi-targeted combination therapies represent a potential avenue for advancing immunotherapy. Among them, bispecific antibodies (BsAbs), which simultaneously target two different antigens or epitopes, have emerged as a focus of attention for their ability to enhance the immune system's recognition and destruction of tumor cells.